Pasireotide, a second-generation somatostatin receptor ligand (sg-SRL), has been associated with impaired glycemic control due to its increased potency in suppressing endogenous insulin secretion, resulting in increased fasting glucose, glycosylated hemoglobin, and prevalence of type 2 diabetes mellitus [100]. Here, INS is linked to diabetes mellitus.